Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on March 28, 2022. The report discloses compensatory arrangements for named executive officers approved by the Board of Directors on the same date, effective April 1, 2022. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
Material Changes and Compensation Details
Based on an analysis by Radford, the Board approved base salary increases to align executive pay with the 25th percentile of comparable companies. Additionally, cash bonuses and equity awards were granted under the 2014 Stock Incentive Plan.
- Base Salary Increases (Effective April 1, 2022):
- Lisa A. Conte (CEO): Increased from $535,700 to $576,374.
- Jonathan S. Wolin (Chief of Staff/GC/CCO): Increased from $344,800 to $396,520.
- Ian Wendt (CCO): Increased from $338,900 to $350,100.
- Cash Bonuses Granted:
- Lisa A. Conte: $160,140
- Jonathan S. Wolin: $104,248
- Ian Wendt: $88,252
- Equity Awards Granted:
- Lisa A. Conte: 606,280 Time-Based RSUs and 25,000 Performance RSUs.
- Jonathan S. Wolin: 196,018 Time-Based RSUs.
- Ian Wendt: 224,783 Time-Based RSUs.
- Tax Reimbursement: A one-time aggregate payment of approximately $24,124 was approved to reimburse executives for estimated taxes on prior awards.
Outlook, Risks, and Vesting Conditions
Vesting Schedules:
- Time-Based RSUs: Vest ratably over three years beginning May 17, 2023, contingent on continued employment.
- Performance RSUs (CEO only): Vest upon successful completion of the pivotal trial of crofelemer (Mytesi) for cancer-therapy related diarrhea and successful completion of investigator-initiated trials for the European early access program.
Risks and Contingencies: The vesting of performance-based equity is contingent on specific clinical trial outcomes. The filing references severance agreements that may impact vesting upon termination.
Investor Verification Checklist
- Verify the impact of the new salary and bonus structure on the company's cash burn rate and operating expenses.
- Monitor the progress of the pivotal crofelemer trial and European early access program trials, as these determine the vesting of CEO performance RSUs.
- Review the 2014 Stock Incentive Plan terms and the referenced Severance Agreement (filed June 26, 2020) to understand acceleration clauses or forfeiture risks.
- Confirm the total number of shares available under the 2014 Plan to assess dilution potential from these grants.